| Filed On | Filing |
|---|---|
| 04 Nov 2026 |
8-K: Results of Operations and Financial Condition
3Q 2026 Total Revenue of $141.1 Million, Increasing 5% Year-over-Year |
| 05 Aug 2026 |
8-K: Results of Operations and Financial Condition
2Q 2026 Total Revenue of $124.4 Million, Increasing 2% Year-over-Year |
| 02 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
ADMA Biologics, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”) on June 2, 2026. At the Annual Meeting, the following matters were submitted to a vote of stockholders: |
| 06 May 2026 |
8-K: Results of Operations and Financial Condition
1Q 2026 Total Revenue of $114.5 Million, Flat Year-Over-Year |
| 04 May 2026 |
8-K: Other Events
ADMA Biologics Announces FDA Approval to Expand the Label for ASCENIVTM to Include Pediatric Immune Compromised Patients Two Years of Age and Older |
| 27 Mar 2026 |
8-K: Regulation FD Disclosure
Short seller’s Characterization of ASCENIV’s Competitive Position Reflects Blatant Misunderstanding of ADMA’s Business and Its Role as Late-line Therapy for Patients Who are Immune Compromised and Therefore, May Not Respond to Vaccines |
| 02 Mar 2026 |
8-K: Regulation FD Disclosure; Other Events
ADMA Biologics Announces $125 Million Accelerated Share Repurchase with JPMorgan as Part of a Planned $200 Million 2026 Total Share Repurchase Initiative |
| 25 Feb 2026 |
8-K: Results of Operations and Financial Condition; Departure/Election of Directors or Officers; Compensation
FY 2025 Total Revenue of $510 Million, Representing 20% Year-Over-Year Growth |
| 12 Jan 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
ADMA Biologics Realizing the Potential of Specialty Biologicswith Groundbreaking Immunotechnology January 2026 NASDAQ: ADMA |
| 05 Nov 2025 |
8-K: Results of Operations and Financial Condition
3Q 2025 Adjusted EBITDA(1) of $58.7 Million, a 29% YoY Increase |
| 06 Aug 2025 |
8-K: Entry into a Material Definitive Agreement; Termination of a Material Definitive Agreement +2 more
Exhibit B-1 – U.S. Tax Compliance Certificate (For Foreign Lenders That Are Not Partnerships For U.S. Federal Income Tax Purposes) |
| 04 Jun 2025 |
8-K: Submission of Matters to a Vote of Security Holders
ADMA Biologics, Inc. (the “Company”) held its 2025 Annual Meeting of Stockholders (the “Annual Meeting”) on June 4, 2025. At the Annual Meeting, the following matters were submitted to a vote of stockholders: |
| 07 May 2025 |
8-K: Results of Operations and Financial Condition; Other Events
1Q 2025 Total Revenue of $114.8 Million (Adjusted Total Revenue(1) of $118.6 Million), a 40% YoY Increase |
| 28 Apr 2025 |
8-K: Other Events
Approval Supports Revenue Growth and Margin Expansion Opportunity, and Substantially Increases Peak Production Output Capacity |
| 03 Mar 2025 |
8-K: Results of Operations and Financial Condition
FY 2024 GAAP Net Income of $197.7 Million, Including an $84.3 Million Valuation Allowance Tax Benefit |
| 21 Feb 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
| 13 Jan 2025 |
8-K: Regulation FD Disclosure
ADMA Biologics Realizing the Potential of Specialty Biologicswith Groundbreaking Immunotechnology January 2025 NASDAQ: ADMA |
| 13 Jan 2025 |
8-K: Results of Operations and Financial Condition
FY 2024 Preliminary Unaudited Total Revenue of Approximately $417-425 Million, Exceeding Previous Guidance of $415 Million |
| 02 Jan 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
| 20 Dec 2024 |
8-K: Other Events
Cash on Hand Utilized to Repay $30 Million of Senior Secured Term Loan Facility to Ares Capital |
Loading...